SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 305 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,901,436 | -0.7% | 89,931 | -6.2% | 0.02% | +13.3% |
| Q2 2023 | $10,974,223 | -24.5% | 95,828 | -9.1% | 0.02% | -31.8% |
| Q1 2023 | $14,536,241 | +4.9% | 105,465 | -1.3% | 0.02% | 0.0% |
| Q4 2022 | $13,851,584 | +14.5% | 106,896 | -2.3% | 0.02% | +10.0% |
| Q3 2022 | $12,100,000 | +51.1% | 109,465 | +2.5% | 0.02% | +53.8% |
| Q2 2022 | $8,006,000 | -3.7% | 106,805 | +0.4% | 0.01% | +18.2% |
| Q1 2022 | $8,314,000 | -15.9% | 106,424 | -3.1% | 0.01% | -8.3% |
| Q4 2021 | $9,890,000 | -16.8% | 109,832 | -14.6% | 0.01% | -20.0% |
| Q3 2021 | $11,891,000 | +15.2% | 128,580 | -3.2% | 0.02% | +15.4% |
| Q2 2021 | $10,324,000 | -2.4% | 132,801 | -6.4% | 0.01% | -7.1% |
| Q1 2021 | $10,575,000 | -56.0% | 141,889 | +0.6% | 0.01% | -58.8% |
| Q4 2020 | $24,045,000 | +25.3% | 141,034 | +3.2% | 0.03% | +9.7% |
| Q3 2020 | $19,197,000 | -13.8% | 136,702 | -1.6% | 0.03% | -20.5% |
| Q2 2020 | $22,276,000 | +82.8% | 138,931 | +11.5% | 0.04% | +50.0% |
| Q1 2020 | $12,186,000 | -26.1% | 124,574 | -2.5% | 0.03% | -7.1% |
| Q4 2019 | $16,482,000 | +92.6% | 127,730 | +12.4% | 0.03% | +64.7% |
| Q3 2019 | $8,559,000 | -49.8% | 113,631 | +1.2% | 0.02% | -50.0% |
| Q2 2019 | $17,060,000 | +36.3% | 112,277 | +6.9% | 0.03% | +30.8% |
| Q1 2019 | $12,518,000 | +9.7% | 105,022 | +0.4% | 0.03% | 0.0% |
| Q4 2018 | $11,411,000 | -26.8% | 104,561 | +8.3% | 0.03% | -13.3% |
| Q3 2018 | $15,599,000 | +23.8% | 96,585 | +1.4% | 0.03% | +15.4% |
| Q2 2018 | $12,596,000 | +82.7% | 95,293 | +2.4% | 0.03% | +73.3% |
| Q1 2018 | $6,896,000 | +28.7% | 93,073 | -3.4% | 0.02% | +36.4% |
| Q4 2017 | $5,360,000 | +24.7% | 96,336 | +1.7% | 0.01% | +10.0% |
| Q3 2017 | $4,299,000 | +38.5% | 94,770 | +2.9% | 0.01% | +42.9% |
| Q2 2017 | $3,104,000 | +6.1% | 92,077 | -6.8% | 0.01% | +16.7% |
| Q1 2017 | $2,925,000 | +3.1% | 98,809 | -4.4% | 0.01% | 0.0% |
| Q4 2016 | $2,837,000 | -49.0% | 103,409 | +14.3% | 0.01% | -45.5% |
| Q3 2016 | $5,558,000 | +225.2% | 90,509 | +1.0% | 0.01% | +175.0% |
| Q2 2016 | $1,709,000 | -7.7% | 89,609 | -5.5% | 0.00% | 0.0% |
| Q1 2016 | $1,851,000 | -42.2% | 94,807 | +14.3% | 0.00% | -50.0% |
| Q4 2015 | $3,200,000 | +31.7% | 82,932 | +9.7% | 0.01% | +33.3% |
| Q3 2015 | $2,429,000 | +5.4% | 75,632 | -0.1% | 0.01% | 0.0% |
| Q2 2015 | $2,305,000 | +133.8% | 75,732 | +2.0% | 0.01% | +200.0% |
| Q1 2015 | $986,000 | -9.6% | 74,229 | -1.6% | 0.00% | -33.3% |
| Q4 2014 | $1,091,000 | -31.2% | 75,429 | +0.4% | 0.00% | -25.0% |
| Q3 2014 | $1,585,000 | -28.4% | 75,108 | +1.1% | 0.00% | -33.3% |
| Q2 2014 | $2,213,000 | +34.9% | 74,282 | +8.8% | 0.01% | +50.0% |
| Q1 2014 | $1,641,000 | +18.3% | 68,282 | +0.3% | 0.00% | 0.0% |
| Q4 2013 | $1,387,000 | -51.3% | 68,082 | +12.9% | 0.00% | -50.0% |
| Q3 2013 | $2,847,000 | +34.5% | 60,282 | +8.4% | 0.01% | +14.3% |
| Q2 2013 | $2,116,000 | – | 55,606 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |